Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.

AIDS

aCentre for Health & Infectious Diseases Research (CHIP), Department of Infectious Diseases and Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark bClinica delle Malattie Infettive, Ospedale L. Sacco, Milan, Italy cDept de Medicine Tropicale, Hopital de la Pitié-Salpêtriére, Paris, France dInstituto de Saúde Ambiental, Faculdade de Medicina de Lisboa eServiço de Doenças Infecciosas, Hospital de Santa Maria, Lisbon, Portugal fDepartment of Infectious Diseases, Wojewodzki Szpital Specjalistyczny, Bialystok, Poland gDepartment of Infectious Diseases, Södersjukhuset Venhälsan, Stockholm, Sweden hInfectious Diseases Department, Gomel State Medical University, Gomel, Belarus iDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland j1st Department of Internal Medicine, Athens General Hospital 'G. Gennimatas', Athens, Greece kDepartment of Infection and Population Health, University College London, London, UK. *Study group listed in the Acknowledgements section.

Published: November 2014

Objective: To assess the relationship between platelet counts and risk of AIDS and non-AIDS-defining events.

Design: Prospective cohort.

Methods: EuroSIDA patients with at least one platelet count were followed from baseline (first platelet ≥ 1 January 2005) until last visit or death. Multivariate Poisson regression was used to assess the relationship between current platelet counts and the incidence of non-AIDS-defining (pancreatitis, end-stage liver/renal disease, cancer, cardiovascular disease) and AIDS-defining events.

Results: There were 62 898 person-years of follow-up (PYFU) among 12 279 patients, including 1168 non-AIDS-defining events [crude incidence 18.6/1000 PYFU, 95% confidence interval (CI) 17.5-19.6] and 735 AIDS-defining events (crude incidence 11.7/1000 PYFU, 95% CI 10.8-12.5). Patients with thrombocytopenia (platelet count ≤100 × 10/l) had a slightly increased incidence of AIDS-defining events [adjusted incidence rate ratio (aIRR) 1.42, 95% CI 1.07-1.86], when compared to those with platelet counts 101-200 × 10/l, whereas the incidence of non-AIDS-defining events was more than two-fold higher (aIRR 2.66, 95% CI 2.17-3.26). Among non-AIDS-defining events, the adjusted incidence of cancer (aIRR 2.20, 95% CI 1.61-3.01), but not cardiovascular disease (aIRR 0.66, 95% CI 0.32-1.34), was significantly higher in patients with thrombocytopenia. The association between thrombocytopenia and cancer remained unaltered in sensitivity analyses requiring repeated platelet counts to confirm thrombocytopenia and lagging platelets by 1 year prior to clinical events.

Conclusion: Patients with thrombocytopenia had increased incidence of AIDS-defining and non-AIDS-defining events, but the association with the latter, in particular cancer, was stronger. Future studies should investigate whether the pathophysiological processes underlying thrombocytopenia are associated with the development of cancer during treated HIV disease.

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000000433DOI Listing

Publication Analysis

Top Keywords

platelet counts
16
non-aids-defining events
16
patients thrombocytopenia
12
thrombocytopenia associated
8
cancer treated
8
treated hiv
8
hiv disease
8
assess relationship
8
platelet count
8
incidence
8

Similar Publications

Aim: Many combinations of inflammation-based markers have been reported their prognostic ability. The prognostic value of albumin-to-gama-glutamyltransferase ratio (AGR), an inflammation-related index, has been identified for several cancers. However, the predictive value of AGR for high-grade glioma patients remains unclear.

View Article and Find Full Text PDF

TRIPLE Score: GPVI and CD36 Expression Predict a Prothrombotic Platelet Function Phenotype.

Circ Res

January 2025

Institute for Cardiovascular and Metabolic Research, Health and Life Sciences Building, University of Reading, United Kingdom. (N.K., C.K., J.L.D., T.S., S.R., M.V.D.A., V.S., N.R., C.I.J., J.M.G.).

View Article and Find Full Text PDF

Prognostication of compensated advanced chronic liver disease (cACLD) is of paramount importance for the physician-and-patient communication and for rational clinical decisions. The paper published by Dallio reports on red cell distribution width (RDW)/platelet ratio (RPR) as a non-invasive biomarker in predicting decompensation of metabolic dysfunction-associated steatotic liver disease (MASLD)-related cACLD. Differently from other biomarkers and algorithms, RPR is inexpensive and widely available, based on parameters which are included in a complete blood count.

View Article and Find Full Text PDF

This letter critically evaluates Jiang 's article on the differentiation of benign and malignant liver lesions using Emax and platelet count. Despite notable findings, significant methodological and interpretative limitations are identified. The study lacks detailed assay conditions for Emax measurement, employs inadequate statistical methods without robust multivariate analysis, and does not provide clinically relevant threshold values.

View Article and Find Full Text PDF

Background: It is uncommon to come across instances of aplastic anemia in individuals suffering from papillary thyroid carcinoma complicated by Hashimoto's thyroiditis. Here, a unique case is presented.

Case Presentation: A 23-year-old male was admitted to the hospital for "a lump in his right neck".

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!